nonmem version 7.5 (ICON plc)
90
Structured Review
ICON plc
nonmem version 7.5
Nonmem Version 7.5, supplied by ICON plc, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/nonmem+(version+7%2E5)/nonmem+version+7+3/pm40474043-39-12-15
Average 90 stars, based on 1 article reviews
Nonmem Version 7.5, supplied by ICON plc, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/nonmem+(version+7%2E5)/nonmem+version+7+3/pm40474043-39-12-15
Average 90 stars, based on 1 article reviews
nonmem version 7.5 - by Bioz Stars,
2026-09
90/100 stars
Images
Related Articles
other:Article Title: Population Pharmacokinetic/Pharmacodynamic and Exposure–Response Modeling of Garadacimab in Healthy Volunteers and Patients With Hereditary Angioedema Article Snippet: Analyses for HAE attacks were conducted via non‐linear mixed effects modeling using Article Title: Effect of Amiodarone on Apixaban Exposure in Patients after Cardiac Surgery-A Population Pharmacokinetic Study. Article Snippet: Aim To investigate the effect of amiodarone on apixaban pharmacokinetics in cardiac surgery patients with postoperative atrial fibrillation.. Methods Apixaban concentrations of postoperative cardiac surgery patients with or without amiodarone therapy were quantified using liquid chromatography–tandem mass spectrometry (LC–MS/MS) in clinical routine.. A population pharmacokinetic model was built using nonlinear mixed effects modeling in NONMEM® 7.5 using first-order conditional estimation with interaction. Article Title: A whole-body mechanistic physiologically-based pharmacokinetic modeling of intravenous iron Article Snippet: The PBPK model was established using Article Title: A whole-body mechanistic physiologically-based pharmacokinetic modeling of intravenous iron. Article Snippet: The PBPK model was established using Article Title: Integrated Two-Analyte Population Pharmacokinetics Model of Patritumab Deruxtecan (HER3-DXd) Monotherapy in Patients with Solid Tumors. Article Snippet: Background and Objective Patritumab deruxtecan (HER3-DXd, also known as MK-1022) is an antibody–drug conjugate comprising a fully human monoclonal antibody against human epidermal growth factor receptor 3 (HER3) attached to a topoisomerase I inhibitor payload, deruxtecan (DXd), via a tetrapeptide-based cleavable linker.. We developed a population pharmacokinetic (PK) model for anti-HER3-ac-DXd (anti-HER3 antibody conjugated DXd) and DXd to characterize their PKs and investigate the impact of preselected covariates.. Methods Data were pooled from four phase I/II studies including patients with breast, lung, and colorectal cancer (N = 733) treated with HER3-DXd monotherapy (1.6–8.0 mg/kg intravenously every 3 weeks). Article Title: Population Pharmacokinetic/Pharmacodynamic and Exposure-Response Modeling of Garadacimab in Healthy Volunteers and Patients With Hereditary Angioedema. Article Snippet: Analyses for HAE attacks were conducted via non- linear mixed effects modeling using Article Title: Population Pharmacokinetic/Pharmacodynamic and Exposure–Response Modeling of Garadacimab in Healthy Volunteers and Patients With Hereditary Angioedema Article Snippet: Analyses for repeated‐measures endpoints were conducted via non‐linear mixed effects modeling using Article Title: Population Pharmacokinetic/Pharmacodynamic and Exposure-Response Modeling of Garadacimab in Healthy Volunteers and Patients With Hereditary Angioedema. Article Snippet: Analyses for repeated- measures endpoints were conducted via non- linear mixed effects modeling using |